Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Choice of Neuromuscular Blockade Reversal Agent and Its Effects on Postoperative Urinary Retention: A Retrospective Cohort Study

NCT06948409 is registered in ClinicalTrials.gov with Beth Israel Deaconess Medical Center as lead sponsor.

NCT NCT06948409
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06948409 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The Choice of Neuromuscular Blockade Reversal Agent and Its Effects on Postoperative Urinary Retention: A Retrospective Cohort Study
Lead sponsor
Beth Israel Deaconess Medical Center
Phase
Observational
Overall status
Active, not recruiting
Start date
June 8, 2025
Completion date
June 1, 2026
Enrollment
70,000 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

anesthesia, atropine, costs, glycopyrrolate, neostigmine, neuromuscular blockade, neuromuscular blockade reversal agent, neuromuscular blocking agents, sugammadex, urinary retention after procedure, urinary retention postoperative